Development and evaluation of a low cost IgG ELISA test based in RBD protein for COVID-19

dc.creatorVillafañe, Luciana María
dc.creatorGallo Vaulet, Maria Lucia
dc.creatorViere, Florencia M.
dc.creatorKlepp, Laura Ines
dc.creatorForrellad, Marina Andrea
dc.creatorBigi, María Mercedes
dc.creatorRomano, Maria Isabel
dc.creatorMagistrelli, Giovanni
dc.creatorRodríguez Fermepin, Marcelo
dc.creatorBigi, Fabiana
dc.date.accessioned2021-12-09T13:43:44Z
dc.date.accessioned2023-03-15T14:12:30Z
dc.date.available2021-12-09T13:43:44Z
dc.date.available2023-03-15T14:12:30Z
dc.date.created2021-12-09T13:43:44Z
dc.date.issued2022-01
dc.identifier0022-1759
dc.identifierhttps://doi.org/10.1016/j.jim.2021.113182
dc.identifierhttp://hdl.handle.net/20.500.12123/10871
dc.identifierhttps://www.sciencedirect.com/science/article/pii/S0022175921002271
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/6213832
dc.description.abstractSerology tests for SARS-CoV-2 have proven to be important tools to fight against the COVID-19 pandemic. These serological tests can be used in low-income and remote areas for patient contact tracing, epidemiologic studies and vaccine efficacy evaluations. In this study, we used a semi-stable mammalian episomal expression system to produce high quantities of the receptor-binding domain-RBD of SARS-CoV-2 in a simple and very economical way. The recombinant antigen was tested in an in-house IgG ELISA for COVID-19 with a panel of human sera. A performance comparison of this serology test with a commercial test based on the full-length spike protein showed 100% of concordance between tests. Thus, this serological test can be an attractive and inexpensive option in scenarios of limited resources to face the COVID-19 pandemic.
dc.languageeng
dc.publisherElsevier
dc.relationinfo:eu-repograntAgreement/INTA/2019-PD-E5-I102-001/2019-PD-E5-I102-001/AR./Desarrollo de vacunas y tecnologías para mejorar las estrategias profilácticas y terapéuticas de las enfermedades que afectan la producción animal y la salud pública
dc.rightsinfo:eu-repo/semantics/embargoedAccess
dc.sourceJournal of Immunological Methods 500 : 113182 (January 2022)
dc.subjectCOVID-19
dc.subjectCoronavirus del Síndrome Respiratorio Agudo Grave 2
dc.subjectDiagnóstico
dc.subjectELISA
dc.subjectTécnicas Inmunológicas
dc.subjectSevere Acute Respiratory Syndrome Coronavirus 2
dc.subjectDiagnosis
dc.subjectImmunological Techniques
dc.titleDevelopment and evaluation of a low cost IgG ELISA test based in RBD protein for COVID-19
dc.typeinfo:ar-repo/semantics/artículo
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/acceptedVersion


Este ítem pertenece a la siguiente institución